Serdemetan enhances bone regeneration by coordinated regulation of osteoblast and osteoclast activity through the p53 pathway

ABSTRACT: Serdemetan, an MDM2 inhibitor traditionally known for anticancer activity, demonstrates dual pro-osteogenic and anti-osteoclastic effects via p53 activation, showing bone regenerative efficacy comparable to alendronate in preclinical models.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE300127 | GEO | 2025/07/10

REPOSITORIES: GEO